^
Association details:
| Biomarker: | AXL overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AXL inhibition improves BRAF-targeted treatment in melanoma
Published date:
03/24/2022
Excerpt:
In the current study, we investigated the therapeutic potential of the AXL inhibitor (AXLi) BGB324 alone or in combination with the clinically relevant BRAF inhibitor (BRAFi) vemurafenib....To investigate the effect of AXLi alone or in combination with BRAFi, three cell lines with high expression of AXL, Melmet 1, A375 (both BRAF-mutated) and WM1366 (BRAF wild type), were selected for further studies. Following treatment with AXLi, all cell lines responded by reducing their metabolic activity that reflects reduced cell viability/proliferation.
DOI:
10.1038/s41598-022-09078-z
